Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia

Division of Hematology/Oncology, University of North Carolina at Chapel Hill, CB no. 7305, 3009 Old Clinic Bldg, Chapel Hill, NC 27599-7305, USA.
Blood (Impact Factor: 9.78). 04/2008; 111(8):3991-7. DOI: 10.1182/blood-2007-08-110098
Source: PubMed

ABSTRACT Senicapoc, a novel Gardos channel inhibitor, limits solute and water loss, thereby preserving sickle red blood cell (RBC) hydration. Because hemoglobin S polymerization is profoundly influenced by intracellular hemoglobin concentration, senicapoc could improve sickle RBC survival. In a 12-week, multicenter, phase 2, randomized, double-blind, dose-finding study, we evaluated senicapoc's safety and its effect on hemoglobin level and markers of RBC hemolysis in sickle cell anemia patients. The patients were randomized into 3 treatment arms: placebo; low-dose (6 mg/day) senicapoc; and high-dose (10 mg/day) senicapoc. For the primary efficacy end point (change in hemoglobin level from baseline), the mean response to high-dose senicapoc treatment exceeded placebo (6.8 g/L [0.68 g/dL] vs 0.1 g/L [0.01 g/dL], P < .001). Treatment with high-dose senicapoc also produced significant decreases in such secondary end points as percentage of dense RBCs (-2.41 vs -0.08, P < .001); reticulocytes (-4.12 vs -0.46, P < .001); lactate dehydrogenase (-121 U/L vs -15 U/L, P = .002); and indirect bilirubin (-1.18 mg/dL vs 0.12 mg/dL, P < .001). Finally, senicapoc was safe and well tolerated. The increased hemoglobin concentration and concomitant decrease in the total number of reticulocytes and various markers of RBC destruction following senicapoc administration suggests a possible increase in the survival of sickle RBCs. This study is registered at as NCT00040677.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Sickle cell disease (SCD) predominates in sub-Saharan Africa, East Mediterranean areas, Middle East, and India. Nigeria, being the most populous black nation in the world, bears its greatest burden in sub-Saharan Africa. The last few decades have witnessed remarkable scientific progress in the understanding of the complex pathophysiology of the disease. Improved clinical insights have heralded development and establishment of disease modifying interventions such as chronic blood transfusions, hydroxyurea therapy, and haemopoietic stem cell transplantation. Coupled with parallel improvements in general supportive, symptomatic, and preventive measures, current evidence reveals remarkable appreciation in quality of life among affected individuals in developed nations. Currently, in Nigeria and other West African states, treatment and control of SCD are largely suboptimal. Improved knowledge regarding SCD phenotypes and its comprehensive care among Nigerian physicians will enhance quality of care for affected persons. This paper therefore provides a review on the aetiopathogenesis, clinical manifestations, and management of SCD in Nigeria, with a focus on its local patterns and peculiarities. Established treatment guidelines as appropriate in the Nigerian setting are proffered, as well as recommendations for improving care of affected persons.
    Anemia 01/2015; 2015:791498. DOI:10.1155/2015/791498
  • [Show abstract] [Hide abstract]
    ABSTRACT: The purpose of these studies was to identify the presence of cystathionine-γ-lyase (CSE) and 3-mercaptopyruvate sulfurtransferase (3-MST), which endogenously produce hydrogen sulfide (H2S), and to functionally examine the mechanisms of H2S-induced vasodilation in the human cutaneous microcirculation. CSE and 3-MST were quantified in forearm skin samples from 5 healthy adults (24±3 yrs) using western blot analysis. For functional studies, microdialysis fibers were placed in the forearm skin of 12 healthy adults (25±3 yrs) for graded infusions (0.01 mM - 100 mM) of sodium sulfide (Na2S) and sodium hydrogen sulfide (NaHS). To define the mechanisms mediating H2S-induced vasodilation, microdialysis fibers were perfused with Ringer's (control), a KATP channel inhibitor, an intermediate KCa channel inhibitor, a non-specific KCa channel inhibitor, or triple blockade. To determine the interaction of H2S-mediated vasodilation with nitric oxide (NO) and cyclooxygenase (COX) signaling pathways, microdialysis fibers were perfused with Ringer's (control), a non-specific NO synthase inhibitor, a non-selective COX inhibitor, or combined inhibition during perfusion of increasing doses of Na2S. CSE and 3-MST were expressed in all skin samples. Na2S and NaHS elicited dose-dependent vasodilation. Non-specific KCa channel inhibition and triple blockade blunted Na2S-induced vasodilation (P<0.05), whereas KATP and intermediate KCa channel inhibition had no effect (P>0.05). Separate and combined inhibition of NO and COX attenuated H2S-induced vasodilation (P<0.05 for all). CSE and 3-MST are expressed in the human microvasculature. Exogenous H2S elicits cutaneous vasodilation mediated by KCa channels and has a functional interaction with both NO and COX vasodilatory signaling pathways.This article is protected by copyright. All rights reserved
    The Journal of Physiology 01/2015; 593(9). DOI:10.1113/JP270054 · 4.54 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Idiopathic pulmonary fibrosis is a common and invariably fatal disease with limited therapeutic options. Ca2+-activated KCa3.1 potassium channels play a key role in promoting TGFß1 and bFGF-dependent profibrotic responses in human lung myofibroblasts (HLMFs). We hypothesised that KCa3.1 channel-dependent cell processes regulate HLMF ¿SMA expression via Smad2/3 signalling pathways.Methods In this study we have compared the phenotype of HLMFs derived from non-fibrotic healthy control lungs (NFC) with cells derived from IPF lungs. HLMFs grown in vitro were examined for ¿SMA expression by immunofluorescence (IF), RT-PCR and flow cytommetry. Basal Smad2/3 signalling was examined by RT-PCR, western blot and immunofluorescence. Two specific and distinct KCa3.1 blockers (TRAM-34 200 nM and ICA-17043 [Senicapoc] 100nM) were used to determine their effects on HLMF differentiation and the Smad2/3 signalling pathways.ResultsIPF-derived HLMFs demonstrated increased constitutive expression of both ¿-smooth muscle actin (¿SMA) and actin stress fibres, indicative of greater myofibroblast differentiation. This was associated with increased constitutive Smad2/3 mRNA and protein expression, and increased Smad2/3 nuclear localisation. The increased Smad2/3 nuclear localisation was inhibited by removing extracellular Ca2+ or blocking KCa3.1 ion channels with selective KCa3.1 blockers (TRAM-34, ICA-17043). This was accompanied by de-differentiation of IPF-derived HLMFs towards a quiescent fibroblast phenotype as demonstrated by reduced ¿SMA expression and reduced actin stress fibre formation.Conclusions Taken together, these data suggest that Ca2+- and KCa3.1-dependent processes facilitate ¿constitutive¿ Smad2/3 signalling in IPF-derived fibroblasts, and thus promote fibroblast to myofibroblast differentiation. Importantly, inhibiting KCa3.1 channels reverses this process. Targeting KCa3.1 may therefore provide a novel and effective approach for the treatment of IPF and there is the potential for the rapid translation of KCa3.1-directed therapy to the clinic.
    Respiratory Research 12/2014; 15(1):155. DOI:10.1186/s12931-014-0155-5 · 3.13 Impact Factor